BioCentury highlights GNS-Alexion partnership
Alexion rebuilding pipeline with big data deals August 10, 2017 – Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) is rebuilding its early stage pipeline with two new deals focused on driving rare disease discovery with big genomic data. The company partnered with Sema4 (New York, N.Y.) for genomic sequencing and licensed the Reverse Engineering and Forward Simulation (REFS) […]
Amgen Ventures Invests in GNS Healthcare to Advance Applications of its REFS™ Causal Machine Learning and Simulation AI Platforms
CAMBRIDGE, Mass.– August 23, 2017 – GNS Healthcare (GNS), a leading precision medicine company, today announced that it has raised an additional $6 million in equity from Amgen Ventures with participation from existing investor Alexandria Real Estate Equities. The funds will be used to further develop the company’s REFS™ causal machine learning and simulation platform and solutions […]
GNS Co-Founder Iya Khalil Interviewed in The Pink Sheet
At the 2017 BIO International Convention, GNS Co-Founder and Chief Commercial Officer Iya Khalil sat down with Laura Helbling, the Director of Research at Prevision Policy and a Senior Writer at Pink Sheet to discuss machine learning in drug development. The conversation focused on how GNS’ causal machine learning and simulation platform applied to massive […]
Sema4 and GNS Healthcare Announce Collaboration Using REFS™ Causal Machine Learning and Simulation AI Platform
Working Towards New Therapies for Cardiovascular Disease Stamford, Conn. and Cambridge, Mass. – June 27, 2017– Sema4, an interdisciplinary health information company with expertise in collecting diverse data, building computational models of disease and unlocking solutions to disease, today announced it is leveraging GNS Healthcare’s (GNS), REFS™ (Reverse Engineering and Forward Simulation) causal machine learning […]
Gregg’s Diabetes Identifies GNS as One of a Handful of Companies Focused on Market Access
The 21st Century Cures Act makes “Real World Evidence” a buzz word in pharma and payer circles, and justifiably so. For the uninitiated, “Real World Evidence” (RWE) is a term that has received much and attention and debate as a core component of the 21st Century Cures Act: a bill that received much press coverage […]
Xconomy Features Celgene-GNS REFS License, Investment Deal
Celgene has made a second investment in GNS Healthcare and is tapping into the firm’s data analytics software to boost Celgene’s drug discovery and development efforts. Read the full story here.
Celgene Enters Into Service and License Arrangement for GNS Healthcare’s Causal Machine Learning Platform to Accelerate Value-Based and Precision Medicine Development
CAMBRIDGE, Mass. – November 29, 2016 – GNS Healthcare (GNS), a leading precision medicine company that applies causal machine learning technology to massive and diverse data streams to better match drugs and other health interventions to individual patients, today announced that Celgene Corporation has entered into a service and license arrangement for the rights to […]
MS News Today Features GNS ‘Efficacy to Effectiveness’ Solution
GNS Healthcare is presenting a data-driven causal machine learning solution, called Efficacy to Effectiveness, designed to predict how potential therapies will actually perform in distinct populations. Read the complete story here.
Modern Healthcare Reports Horizon Investment in GNS, Notes Diverse Stakeholders Among GNS Investors
Another Blues plan has invested in a small Cambridge, Mass.-based company that uses big data and computer modeling to help clinicians and researchers target treatments to individuals. Read the full article here.
GNS Healthcare Announces Investment by Horizon Healthcare Services, Inc. to Expand Strategic Partnership Focused on Precision Medicine in Population Health
CAMBRIDGE, Mass. – May 23, 2016 – GNS Healthcare (GNS), a leading precision medicine company that applies causal machine learning technology to match health interventions to individual patients and discover new target intervention pathways, today announced an investment by Horizon Healthcare Services, Inc. (New Jersey). The investment supports a strategic collaboration between the companies and […]